Giving dates to pregnant women as an efforts to increase hemoglobin levels
DOI:
https://doi.org/10.59247/jppmi.v2i10.154Keywords:
Dates, Mild Anemia, Pregnant WomenAbstract
Anemia of pregnancy is a maternal condition with hemoglobin (Hb) levels <11 g% in the I and III trimesters or hemoglobin (Hb) levels below 11 g% in the I and III trimesters or levels < 10.5 g% in the second trimester. Anemia in pregnant women has a negative impact on both the mother and the fetus. Adverse effects on the mother are the occurrence of premature birth, low birth weight babies, infant mortality, time of parturition due to lack of uterine propulsion. Based on the author's experience when providing guidance to midwifery students who practice midwifery clinics, there are still pregnant women who do not take blood-boosting tablets because the side effects of these tablets are nausea, black bowel movements. So the mother is lazy to consume the blood-boosting tablet. The results of research regarding offering dates to pregnant women with mild anemia found that the average hemoglobin level of pregnant women before being given dates was 9.17 gr% with a standard deviation of 0.83gr%. While the average hemoglobin level of pregnant women after being given dates is 10.15gr% with a standard deviation of 0.800 gr%. The difference value before and before being given fruit is -0.983 with a standard deviation of 0.278. The results of the statistical test value of 0.001 means that there is a significant difference between Hb levels before and before being given dates. Giving dates to pregnant women as an effort to increase hemoglobin levels has been scientifically proven, therefore it is necessary to do community service by targeting a group of first trimester pregnant women who experience mild anemia and will be offered dates for 3 months at the Arrabih Pratama Clinic. After giving knowledge and offering dates to 10 pregnant women, they got changes and increases in hemoglobin levels ranging from 0.5 to 1.5 g%. It is expected to present dates that can be used as a method of midwifery care for pregnant women for the prevention of anemia.
References
N. Chen et al., “Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis,” N. Engl. J. Med., vol. 381, no. 11, pp. 1011–1022, Sep. 2019.
G. Weiss, T. Ganz, and L. T. Goodnough, “Anemia of inflammation,” Blood, vol. 133, no. 1, pp. 40–50, Jan. 2019.
N. Chen et al., “Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis,” N. Engl. J. Med., vol. 381, no. 11, pp. 1001–1010, Sep. 2019.
C. M. Chaparro and P. S. Suchdev, “Anemia epidemiology, pathophysiology, and etiology in low‐ and middle‐income countries,” Ann. N. Y. Acad. Sci., p. nyas.14092, Apr. 2019.
N. S. Sanghani and V. H. Haase, “Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience,” Adv. Chronic Kidney Dis., vol. 26, no. 4, pp. 253–266, Jul. 2019.
C. D. Richardson et al., “CRISPR–Cas9 genome editing in human cells occurs via the Fanconi anemia pathway,” Nat. Genet., vol. 50, no. 8, pp. 1132–1139, Aug. 2018.
R. Peffault de Latour et al., “Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia,” N. Engl. J. Med., vol. 386, no. 1, pp. 11–23, Jan. 2022.
G. M. Chertow et al., “Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD,” N. Engl. J. Med., vol. 384, no. 17, pp. 1589–1600, Apr. 2021.
U. Jäger et al., “Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting,” Blood Rev., vol. 41, p. 100648, May 2020.
B. A. Patel et al., “Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study,” Blood, vol. 139, no. 1, pp. 34–43, Jan. 2022.
Z. Tao et al., “Anemia is associated with severe illness in COVID‐19: A retrospective cohort study,” J. Med. Virol., vol. 93, no. 3, pp. 1478–1488, Mar. 2021.
P. E. Taneri et al., “Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis,” Eur. J. Epidemiol., vol. 35, no. 8, pp. 763–773, Aug. 2020.
D. H. Henry et al., “Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study,” Am. J. Hematol., vol. 97, no. 2, pp. 174–184, Feb. 2022.
G. Ducrocq et al., “Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia,” JAMA, vol. 325, no. 6, p. 552, Feb. 2021.
L. Dixon et al., “COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia,” Neurol. - Neuroimmunol. Neuroinflammation, vol. 7, no. 5, p. e789, Sep. 2020.
Y. Xu et al., “Carbon Dots as a Potential Therapeutic Agent for the Treatment of Cancer‐Related Anemia,” Adv. Mater., vol. 34, no. 19, p. 2200905, May 2022.
K.-U. Eckardt et al., “Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis,” N. Engl. J. Med., vol. 384, no. 17, pp. 1601–1612, Apr. 2021.
K. Shubham, T. Anukiruthika, S. Dutta, A. V. Kashyap, J. A. Moses, and C. Anandharamakrishnan, “Iron deficiency anemia: A comprehensive review on iron absorption, bioavailability and emerging food fortification approaches,” Trends Food Sci. Technol., vol. 99, pp. 58–75, May 2020.
S. He, T. Wang, C. Shi, Z. Wang, and X. Fu, “Network pharmacology-based approach to understand the effect and mechanism of Danshen against anemia,” J. Ethnopharmacol., vol. 282, p. 114615, Jan. 2022.
S. Fishbane et al., “Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study,” J. Am. Soc. Nephrol., vol. 32, no. 3, pp. 737–755, Mar. 2021.
M. Wolf et al., “Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia,” JAMA, vol. 323, no. 5, p. 432, Feb. 2020.
M. E. Nellis et al., “Executive Summary of Recommendations and Expert Consensus for Plasma and Platelet Transfusion Practice in Critically Ill Children: From the Transfusion and Anemia EXpertise Initiative—Control/Avoidance of Bleeding (TAXI-CAB),” Pediatr. Crit. Care Med., vol. 23, no. 1, pp. 34–51, Jan. 2022.
A. K. Singh et al., “Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis,” N. Engl. J. Med., vol. 385, no. 25, pp. 2313–2324, Dec. 2021.
R. Bellmann-Weiler et al., “Prevalence and Predictive Value of Anemia and Dysregulated Iron Homeostasis in Patients with COVID-19 Infection,” J. Clin. Med., vol. 9, no. 8, p. 2429, Jul. 2020.
C. Vlasschaert et al., “Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease,” J. Am. Soc. Nephrol., vol. 33, no. 5, pp. 985–995, May 2022.
J. L. Babitt et al., “Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference,” Kidney Int., vol. 99, no. 6, pp. 1280–1295, Jun. 2021.
T. Akizawa, M. Iwasaki, Y. Yamaguchi, Y. Majikawa, and M. Reusch, “Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan,” J. Am. Soc. Nephrol., vol. 31, no. 7, pp. 1628–1639, Jul. 2020.
S. Fishbane et al., “Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study,” J. Am. Soc. Nephrol., vol. 33, no. 4, pp. 850–866, Apr. 2022.
S. Safiri et al., “Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019,” J. Hematol. Oncol., vol. 14, no. 1, p. 185, Nov. 2021.
R. T. Means, “Iron Deficiency and Iron Deficiency Anemia: Implications and Impact in Pregnancy, Fetal Development, and Early Childhood Parameters,” Nutrients, vol. 12, no. 2, p. 447, Feb. 2020.
T. M. Murdych, “A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS‐CoV‐2 vaccine,” Int. J. Lab. Hematol., vol. 44, no. 1, Feb. 2022.
E. Shutov et al., “Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS),” Nephrol. Dial. Transplant., vol. 36, no. 9, pp. 1629–1639, Aug. 2021.
L. Alzubaidi, M. A. Fadhel, O. Al-Shamma, J. Zhang, and Y. Duan, “Deep Learning Models for Classification of Red Blood Cells in Microscopy Images to Aid in Sickle Cell Anemia Diagnosis,” Electronics, vol. 9, no. 3, p. 427, Mar. 2020.
G. Trudel, N. Shahin, T. Ramsay, O. Laneuville, and H. Louati, “Hemolysis contributes to anemia during long-duration space flight,” Nat. Med., vol. 28, no. 1, pp. 59–62, Jan. 2022.
M. M. Y. Wong et al., “Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated,” Clin. Kidney J., vol. 13, no. 4, pp. 613–624, Aug. 2020.
L. Lanser et al., “Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer,” Front. Immunol., vol. 11, Feb. 2020.
R. Bissinger, A. A. M. Bhuyan, S. M. Qadri, and F. Lang, “Oxidative stress, eryptosis and anemia: a pivotal mechanistic nexus in systemic diseases,” FEBS J., vol. 286, no. 5, pp. 826–854, Mar. 2019.
S. Fishbane and B. Spinowitz, “Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018,” Am. J. Kidney Dis., vol. 71, no. 3, pp. 423–435, Mar. 2018.
A. Pagani, A. Nai, L. Silvestri, and C. Camaschella, “Hepcidin and Anemia: A Tight Relationship,” Front. Physiol., vol. 10, Oct. 2019.
J. de la Fuente et al., “Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative,” Biol. Blood Marrow Transplant., vol. 25, no. 6, pp. 1197–1209, Jun. 2019.
A. Gafter-Gvili, A. Schechter, and B. Rozen-Zvi, “Iron Deficiency Anemia in Chronic Kidney Disease,” Acta Haematol., vol. 142, no. 1, pp. 44–50, 2019.
J. C. Ulirsch et al., “The Genetic Landscape of Diamond-Blackfan Anemia,” Am. J. Hum. Genet., vol. 103, no. 6, pp. 930–947, Dec. 2018.
A. M. Wiegersma, C. Dalman, B. K. Lee, H. Karlsson, and R. M. Gardner, “Association of Prenatal Maternal Anemia With Neurodevelopmental Disorders,” JAMA Psychiatry, vol. 76, no. 12, p. 1294, Dec. 2019.
R. Stauder, P. Valent, and I. Theurl, “Anemia at older age: etiologies, clinical implications, and management,” Blood, vol. 131, no. 5, pp. 505–514, Feb. 2018.
I. S. Anand and P. Gupta, “Anemia and Iron Deficiency in Heart Failure,” Circulation, vol. 138, no. 1, pp. 80–98, Jul. 2018.
N. S. Young, “Aplastic Anemia,” N. Engl. J. Med., vol. 379, no. 17, pp. 1643–1656, Oct. 2018.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Miratu Megasari, Ani Trianab
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
